The peptide endothelin receptor antagonist, TAK-044, produces sustained inhibition of endothelin-1 mediated arteriolar vasoconstriction

What Was Tested

Researchers studied Endothelin-1 in this randomized controlled trial publication.

Endothelin-1 (ET-1) has been implicated in the pathophysiology of a number of cardiovascular diseases for which endothelin receptor antagonists are currently under clinical development.

The researchers have previously reported that systemic administration of the combined endothelin A/B receptor antagonist, TAK-044, abolishes the forearm vasoconstriction caused by intrabrachial ET-1 infusion for at least 3 h.

In this study the researchers investigated whether TAK-044 can inhibit ET-1 mediated forearm vasoconstriction for longer periods.

Who Took Part

The age groups tagged for this paper are adults, men only.

Eighteen subjects were recruited to a randomized, placebo-controlled, single-blind, three-way, crossover study.

Subjects were divided into three groups of six.

How the Study Was Run

The researchers set it up as a randomized, single-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Endothelin-1 and who got the comparison, which limits bias.

In this single-blind Endothelin-1 study one party knew the assignments and the other did not.

A placebo (an inactive look-alike) gave the Endothelin-1 group a baseline to be compared against.

Each person switched between Endothelin-1 and the comparison at some point, usually with a gap in between.

On a third occasion subjects received only placebo before intra-arterial ET-1 infusion.

Forearm vasoconstriction to ET-1 was measured by venous occlusion plethysmography.

What Was Measured

The subject headings attached to it are Arterioles, Blood Pressure, Endothelin Receptor Antagonists, Endothelin-1, Forearm, Heart Rate and Hemodynamics.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Endothelin-1.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1997 (British journal of clinical pharmacology), a journal based in England.

More context: the Endothelin-1 compound page, all human trials.